| Detected | Trial | Change |
|---|---|---|
| 2026-06-10 | NCT07468071 Rollover Study for Participants Who Have Been Treated With and Are Continuing to Benefit… |
Recruitment opened |
| 2026-05-15 | NCT05445843 Study of Efficacy and Safety of JDQ443 Single-agent as First-line Treatment for Patients… |
Trial sites reduced: 53 -> 45 locations |
| 2026-05-15 | NCT05445843 Study of Efficacy and Safety of JDQ443 Single-agent as First-line Treatment for Patients… |
date change Completion moved earlier: 2027-11-30 -> 2026-12-31 |
| NCT ID | Title | Condition | Status |
|---|---|---|---|
| Phase 3 | |||
| NCT05132075 | Study of JDQ443 in Comparison With Docetaxel in Participants With Locally Advanced or… | Non-Small Cell Lung Cancer | Active, Not Recruiting |
| Phase 2 | |||
| NCT05714891 | Neoadjuvant Platform Trial in Non-Small Cell Lung Cancer | NSCLC | Active, Not Recruiting |
| NCT05445843 | Study of Efficacy and Safety of JDQ443 Single-agent as First-line Treatment for Patients… | Locally Advanced or Metastatic KRAS G12C-mutated NSCLC With a PD-L1 Expression <1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation | Active, Not Recruiting |
| Phase 1/2 | |||
| NCT07468071 | Rollover Study for Participants Who Have Been Treated With and Are Continuing to Benefit… | Locally Advanced or Metastatic KRAS G12C-mutated Non-small Cell Lung Cancer | Recruiting |
| NCT04699188 | Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation | KRAS G12C Mutant Solid Tumors | Active, Not Recruiting |
| NCT05358249 | Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring… | KRAS G12C Mutant Solid Tumors | Active, Not Recruiting |